Efficacy of Up-Front Chemotherapy in High-Risk Breast Cancer
Author Information
Author(s): E van der Wall, EJT Rutgers, MJ Holtkamp, JW Baars, JH Schornagel, JL Peterse, JH Beijnen, S Rodenhuis
Primary Institution: The Netherlands Cancer Institute
Hypothesis
The study aims to document the efficacy and feasibility of dose-intensive epidoxorubicin in combination with standard doses of 5-fluorouracil and cyclophosphamide as up-front chemotherapy in high-risk breast cancer patients.
Conclusion
The study found that the up-front chemotherapy regimen is well tolerated and highly effective, achieving a 90% clinical objective response rate.
Supporting Evidence
- Thirteen patients achieved a clinical complete response (20%).
- Of the 46 patients with a clinical partial response, one had sclerosis only and four had DCIS.
- None of the patients progressed during chemotherapy.
- The major toxicity was moderate bone marrow suppression with a median WBC nadir of 1800.
- The full planned dose could be given without delays in 66 of 70 patients.
- The overall clinical objective response rate was 90%.
- The pathological complete response was observed in three (5%) of all patients.
- Absence of invasive carcinoma was found in 10% of patients.
Takeaway
This study tested a special chemotherapy for young women with a serious type of breast cancer, and it worked really well for most of them.
Methodology
Patients received three courses of chemotherapy consisting of 5-fluorouracil, epidoxorubicin, and cyclophosphamide at 21-day intervals without haematopoietic growth factors.
Limitations
The study design does not allow conclusions regarding the duration of the response.
Participant Demographics
All patients were below 60 years of age and had not received prior chemotherapy or radiotherapy.
Statistical Information
Confidence Interval
74-98%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website